ImmuPharma plc (LON:IMM – Get Free Report) shares were up 189.1% during mid-day trading on Thursday . The company traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.47 ($0.04). Approximately 107,693,047 shares traded hands during trading, an increase of 471% from the average daily volume of 18,858,229 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Price Performance
The firm has a market capitalization of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53. The business has a 50 day moving average of GBX 1.40 and a 200 day moving average of GBX 1.65.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Stories
- Five stocks we like better than ImmuPharma
- P/E Ratio Calculation: How to Assess Stocks
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is a SEC Filing?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- There Are Different Types of Stock To Invest In
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png&h=45&w=95&zc=2){kind=logo}